Key result
Beta-blockers improve outcomes in mild to moderate heart failure when added to standard therapy, while angiotensin II receptor antagonists and spironolactone show promise for future therapy.
Why the study?
Do new pharmacological agents such as beta-blockers, ARBs, and spironolactone improve outcomes in patients with heart failure compared to standard therapy alone?
Do new pharmacological agents such as beta-blockers, ARBs, and spironolactone improve outcomes in patients with heart failure compared to standard therapy alone?
This review highlights the emerging role of beta-blockers, ARBs, and spironolactone as additions to standard therapy for the management of heart failure.
May support beta-blockers added to standard therapy in mild-moderate HF; leaves open ARBs and spironolactone pending randomized trials.
Since the publication of the Agency for Health Care Policy and Research Guidelines for treatment of heart failure, a number of new agents have been investigated for this indication. β-blockers have now been shown to improve outcomes in mild to moderate heart failure when added to standard therapy. Angiotensin II receptor antagonists have also been investigated and show promise. In general, calcium channel blockers are second-or third-line agents in patients refractory to other therapy. Investigational agents including spironolactone may also hold promise for future therapy.
No takes yet. Share an insight, caveat, or question.
Sharon LaForest (2000) conducted a review in Heart failure. Pharmacological agents (β-blockers, Angiotensin II receptor antagonists, calcium channel blockers, spironolactone) was evaluated. Beta-blockers improve outcomes in mild to moderate heart failure when added to standard therapy, while angiotensin II receptor antagonists and spironolactone show promise for future therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: